Alamar Biosciences is a privately held life sciences company with a mission to transform the field of proteomics to enable the early detection of cancer and other diseases. The company's two proprietary technology platforms, NULISA and Attobody, work seamlessly with the latest advances in genomics to achieve single-digit attomolar detection sensitivity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/08/21 | $80,000,000 | Series B |
Illumina Ventures Morningside Venture Qiming Venture Partners Samsara BioCapital Sherpa Healthcare Partners  | undisclosed |
